Levalbuterol: Pharmacologic properties and use in the treatment of pediatric and adult asthma

Annals of Allergy, Asthma and Immunology

Volumn 90, Issue 6, 2003, Pages 583-592

  Berger, William E ^a  

^a Southern California Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVALBUTEROL; SALBUTAMOL;

ADULT; ASTHMA; BRONCHODILATATION; CHILD; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EMERGENCY MEDICINE; HUMAN; PEER REVIEW; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0037841284     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1081-1206(10)61859-5     Document Type: Review

References (71)

1. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8.
2. Mannino DM, Homa DM, Pertowski CA, Ashizawa A, Nixon LL, et al. Surveillance for asthma-United States, 1960-1995. MMWR CDC Surveill Summ. 1998;47:1-27.
3. 2-adrenergic receptors. Clin Rev Allergy Immunol. 1996;14:37-45.
4. Handley DA, Morley J, Nelson H. Single isomer β-agonists. J Allergy Clin Immunol. 2000;31:64-67.
5. Canning B. Pharmacological properties of (S)-albuterol (ALB) in human airway smooth muscle (HASM) preparations. Am J Respir Crit Care Med. 2002;165:A770.
6. Mitra S, Ugur M, Ugur O, Goodman HM, McCullough Jr, Yamaguchi H. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol. 1998;53:347-354.
7. Ameredes BT, Hershman KL, Brown D, et al. GM-CSF production by human airway smooth muscle cells treated with (R)- and (S)-enantiomers of albuterol. Am J Respir Crit Care Med. 2001;163:A513.
8. 2-agonists on Ach release and smooth muscle contraction in the trachea. Am J Physiol. 1998;274:L32-L38.
9. Agrawal DK. Detrimental effect of (SS)-formoterol and (S)-albuterol is due to an increase in Gi-α1 and Gi-α3 proteins and activation of NF-κB in human airway smooth muscle cells. Am J Respir Crit Care Med. 2002;165:A317.
10. Keir SD, Spina D, Page CP. A comparison of the effects of RS- and S-albuterol on airway responses in immunized guinea pigs. Am J Respir Crit Care Med. 1999;159:A875.
11. Keir SD, Spina D, Page CP. The effect of subcutaneous chronic infusion with R-, S- and RS-salbutamol on airway responsiveness to histamine, bradykinin, and leukotriene C4 in the guinea pig. Br J Pharmacol. 1999;127(Suppl):78P.
12. Hershman KM, Neely CM, Ameredes BT, Calhoun WJ. Regulation of extracellular matrix components by β-agonist isomer. Am J Respir Crit Care Med. 2001;163:A473.
13. Peterson BT, Miller EJ. Effects of enantiomers of albuterol on lung epithelial permeability. Am J Respir Crit Care Med. 2000; 161:A416.
14. Leff AR, Herrnreiter A, Naclerio RM, Baroody FM, Handley DA, Munoz NM. Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pulm Pharmacol Ther. 1997;10:97-104.
15. Volcheck GW, Gleich GJ, Kita H. Pro- and anti-inflammatory effects of β adrenergic agonists on eosinophil response to IL-5. J Allergy Clin Immunol. 1998;111:S35.
16. Agrawal DK, Clark KC, Townley RG. Differential effects of albuterol enantiomers on pulmonary functions and bronchoalveolar lavage (BAL) eosinophilia. Am J Respir Crit Care Med. 2000;161:A191.
17. 2-agonist isomers, has stimulatory effects on mucin secretion and changes in gene expression on airway epithelium. Am J Respir Crit Care Med. 2001;161:A144.
18. + T lymphocytes contribute to the pathology of asthma death. Am J Respir Crit Care Med. 2001;164:560-564.
19. Temann UA, Prasad B, Gallup MW, Basbaum C, Ho SB, et al. A novel role for murine IL-4 in vivo: induction of MUC5AC gene expression and mucin hypersecretion. Am J Respir Cell Mol Biol. 1997;16:471-478.
20. Shimura S, Andoh Y, Haraguchi M, Shirato K. Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. Eur Respir J. 1996;9:1395-1401.
21. National Institutes of Health, National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: NIH, 1997. Publication no 97-4051.
22. Cho SH, Hartleroad JY, Oh CK. (S)-Albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol. 2001;124:478-484.
23. Baramki D, Koester J, Anderson A, Borish L. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomer are negated in the presence of the (S)-isomer. J Allergy Clin Immunol. 2002;109:449-454.
24. 2-agonist enantiomers of albuterol. J Allergy Clin Immunol. 2000;105:S292-S293.
25. Cairns CB, Hamiel C, Musters RJ, et al. Attenuation of inflammation-induced changes in human neutrophils by albuterol is isomeric specific. Am J Respir Crit Care Med. 2001;163:A591.
26. Kwong CC, Chung QN, Choi SS, et al. Effects of the isomers of albuterol, R-albuterol and S-albuterol, on human granulocyte function. J Invest Med. 2002;50:72A.
27. Johansson F, Rydberg I, Aberg G, Andersson RG. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol. 1996;14:57-64.
28. Templeton AG, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther. 1998;11:1-6.
29. Center for Drug Evaluation Research (CDER), Food and Drug Administration. Summary Basis of Approval for Xopenex (levalbuterol HCl). Rockville, MD, 1999.
30. Walle T, Walle UK, Thornburg KR, Schey KL. Stereoselective sulfation of albuterol in humans. Biosynthesis of the sulfate conjugate by HEP G2 cells. Drug Metab Dispos. 1993;21: 76-80.
31. Walle UK, Pesola GR, Walle T. Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal, and platelet activity. Br J Clin Pharmacol. 1993;35:413-418.
32. Eaton EA, Walle UK, Wilson HM, Aberg G, Walle T. Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol. 1996;41:201-206.
33. Boulton DW, Fawcett JP. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol. 1996;41:35-40.
34. Anderson PJ, Zhou X, Breen P, Gann L, Logsdon TW. Pharmacokinetics of (R, S)-albuterol after aerosol inhalation in healthy adult volunteers. J Pharm Sci. 1998;87:841-844.
35. Schmekel B, Rydberg I, Norlander B, Sjosward KN, Ahlner J, Anderson RG. Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers. Eur Respir J. 1999;13:1230-1235.
36. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol. 1998;38:1096-1106.
37. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther. 1999;12:353-362.
38. Xopenex (levalbuterol HCI) Inhalation Solution [package insert]. Marlborough, MA: Sepracor Inc; 2001.
39. Maier G, Henry A, Baumgartner R, et al. The effect of the distomer, (S)-albuterol, is not through alteration of the pharmacokinetics of (R)-albuterol: a population PK analysis. J Allergy Clin Immunol. 2002;109:S237.
40. Dhand R, Goode M, Reid R, Fink JB, Fahey PJ, Tobin MJ. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med. 1999;160:1136-1141.
41. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol. 1999;103:615-621.
42. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol. 2001;108:938-945.
43. Carl JC, Myers T, Kercsmar C. Comparison of levalbuterol and racemic albuterol for the treatment of acute asthma in pediatric patients. Chest. 2001:120(Suppl):137S.
44. Perrin-Fayolle M. Salbutamol in the treatment of asthma. Lancet. 1995;346:1101.
45. Ramsay CM, Cowan J, Flannery E, McLachlan C, Taylor DR. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol. 1999;55:353-359.
46. Cockcroft DW, Swystun VA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax. 1997;52:845-848.
47. Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998;102:943-952.
48. 2-adrenergic medication in acute asthma attack? J Investig Allergy Clin Immunol. 1998;8:30-34.
49. Zorc JJ, Pusic MV, Ogborn CJ, Lebet R, Duggan AK. Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics. 1999;103:748-752.
50. Lotvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca GP, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol. 2001;108:726-731.
51. Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol. 2001;108:681-684.
52. Asmus MJ, Hendeles L, Weinberger M, Ahrens RC, Bisgaard H. Levalbuterol has not been established to have therapeutic advantages over racemic albuterol. J Allergy Clin Immunol. 2002;110:325.
53. Chowdhury BA. Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma. J Allergy Clin Immunol. 2002;110:324.
54. Milgrom H, Skoner D, Bensch G, Kim K, Claus R, Baumgartner R. Reply. J Allergy Clin Immunol. 2002;110:325-328.
55. Federal Register. Vol. 59, No. 216, Wednesday, November 9, 1994:55972-55976.
56. Vaickus L, Schaefer K, Claus R. Impact of decreasing doses of racemic albuterol and levalbuterol on efficacy: a pooled analysis. J Allergy Clin Immunol. 2002;109:S236.
57. Nowak RM, Emerman CL. Levalbuterol is effective in acute asthma. Am J Respir Crit Care Med. 2001;163:A590.
58. 1 in the Emergency Department. Acad Emerg Med. 2002;9:404.
59. Truitt TJ, Witko J, Kotter S, Gordon I. Levalbuterol reduces total and breakthrough treatments in hospitalized patients. Am J Respir Crit Care Med. 2000;161:A553.
60. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest. 2003;123:128-135.
61. Haider D. Levalbuterol affords superior health and cost benefit over racemic albuterol in the emergency department. Respir Care. 2001;46:1081.
62. Murphy M, Piskorski W, Eck C. Levalbuterol (lev) is compatible with ipratropium bromide (IB) and cromolyn sodium (CS): results of a mixing study. Respir Care. 1999;44:1288.
63. Downes H, Hirchman L. Importance of calcium in citric acid induced airway constriction. J Appl Physiol. 1983;55:1496-1500.
64. Downes H, Hirchman L. Calcium chelators increase airway responsiveness. J Appl Physiol. 1985;59:92-95.
65. Miszkiel KA, Beasley R, Holgate ST. The influence of ipratropium bromide and sodium cromoglycate on benzalkonium chloride-induced bronchoconstriction in asthma. Br J Clin Pharmacol. 1988;26:295-301.
66. Zhang YG, Wright WJ, Tam WK, Nguyen-Dank TH, Salome CM, Woolcock AJ. Effect of inhaled preservatives on asthmatic subjects. II. Benzalkonium chloride. Am Rev Respir Dis. 1990;141:1405-1408.
67. Food and Drug Administration, Center for Drug Evaluation and Research. Public Health Advisory: Contamination of Multidose Bottles of Albuterol Sulfate Solution for Inhalation (0.5%). April 19, 2002.
68. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997;156:787-793.
69. Stanford R, McLaughlin T, Okamoto LJ. The cost of asthma in the emergency department and hospital. Am J Respir Crit Care Med. 1999;160:211-215.
70. Strauss L, Hejal R, Galan G, Dixon L, McFadden ER Jr. Observations on the effects of aerosolized albuterol in acute asthma. Am J Respir Crit Care Med. 1997;155:454-458.
71. Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol. 1992;13:95-100.